R&D News | pharmaphorum

News

GSK asthma hope depemokimab works in second indication

GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

News

Sanofi in talks to sell stake in consumer health spinout

Rumours that Sanofi was in discussion with private equity groups over the sale of its consumer health business Opella have been confirmed – at least partially.

News

Ono, Boehringer add to cancer pipelines with licensing deals

Ono Pharma and Boehringer Ingelheim both added to their cancer pipelines, licensing drugs from LigaChem Bio and Circle Pharma, respectively.

News

City Therapeutics' $135m debut, and other bio financing news

Our round-up of recent biotech financings features a strong first round for City Therapeutics, a new RNAi venture led by biotech doyen John Maraganore, and additional cash for Purespring, J

News

Lilly names Thomas Fuchs as its first chief AI officer

Eli Lilly has named Thomas Fuchs as its first-ever chief artificial intelligence officer (CAIO), bolstering the digital representation in the group's C-suite.

News

Sage takes another hit as Alzheimer's drug is canned

Sage Therapeutics has said it will stop the development of dalzanemdor in Alzheimer's disease, a few months after pulling the plug on the drug in Parkinson's disease.

GSK asthma hope depemokimab works in second indication

Sanofi in talks to sell stake in consumer health spinout

Ono, Boehringer add to cancer pipelines with licensing deals

City Therapeutics' $135m debut, and other bio financing news

Lilly names Thomas Fuchs as its first chief AI officer

Sage takes another hit as Alzheimer's drug is canned

Senju launches first-in-class dry eye disease drug in Japan

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks